Globalpharma Announces Bold Expansion Plans with 25 New Product Launches in 2025
Globalpharma, a leading pharmaceutical manufacturer in the UAE and a subsidiary of Dubai Investments PJSC, has revealed its ambitious expansion strategy for 2025. The company plans to launch 25 new products spanning key therapeutic areas, including diabetes, cardiovascular health, gastroenterology, and orthopedics. This initiative underscores Globalpharma's commitment to addressing the region's evolving healthcare needs with innovative and accessible solutions.
Transformative Vision
“Globalpharma’s growth aligns with Dubai Investments’ vision of transforming key industries,” said Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries & Masharie and Board Director of Globalpharma. “The pharmaceutical sector’s rapid expansion presents significant opportunities, and Globalpharma is strategically positioned to capitalize on these. By focusing on innovation, partnerships, and patient-centric solutions, we aim to establish Dubai Investments as a global leader in the pharmaceutical landscape.”
Enhanced Distribution and Market Access
To support its growth, Globalpharma is enhancing its distribution network to ensure seamless access to its products. By optimizing delivery channels and forging new partnerships, the company is committed to meeting the needs of healthcare practitioners and patients. Additionally, refined market entry strategies are helping the company strengthen its presence in key territories while exploring new markets.
“Our focus in 2025 is innovation, accessibility, and collaboration,” said Basem Albarahmeh, General Manager of Globalpharma. “The introduction of 25 new products highlights our dedication to tackling the region's healthcare challenges. By expanding our nutraceutical and women’s health portfolios and refining market strategies, we are setting the stage for sustained growth.”
Building on 2024 Successes
Globalpharma’s momentum for 2025 follows the successful launch of several innovative products in 2024. Notable launches include:
- Glovadip (Valsartan + Amlodipine) and RUSET (Rosuvastatin + Ezetimibe) for cardiovascular health.
- Uriout (Febuxostat) for chronic gout management.
- MG21 and CG21, inspired by UAE heritage, featuring blends of myrrh, costus, and cloves.
These products exemplify the company’s commitment to innovation and addressing critical healthcare needs.
Industry Engagement
Globalpharma will also participate in DUPHAT 2025, a premier pharmaceutical and healthcare event, where it will showcase its latest solutions and engage with industry leaders. This platform reinforces Globalpharma’s commitment to collaboration and innovation, advancing its mission to deliver high-quality healthcare solutions.
